Former Bristol-Myers Squibb man becomes head of Savient Europe

pharmafile | January 18, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  BMS, Savient 

Savient Pharmaceuticals has appointed David Veitch as the new president of its European division.

Veitch joins the specialist biopharma firm with over 24 years of pharma experience at Bristol-Myers Squibb and formerly SmithKline Beecham. 

Most recently he served as senior vice president of European marketing and brand commercialisation at BMS. Prior to that, Veitch spent ten years serving in a number of leadership positions at the US firm. 

He received his Bachelor of Science degree from Bristol University, England. 

Advertisement

He will report directly to John Johnson, chief executive and president of Savient, and will be responsible for establishing, building and leading Savient’s European regional organisation to launch its gout drug Krystexxa. 

Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Elekta and BMS partner for digital treatment for melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

The Gateway to Local Adoption Series

Latest content